Project Grant R44CA261523
Award Date
4/1/21
Completion Date
5/11/21
Dollars Obligated
$1.8M
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
This Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $440,287 to GE Medical Systems Information Technologies, Inc. to establish a simplified and accessible procedure for multi-analyte simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. This approach aims to democratize biobanking for low-resource institutes by enabling molecular analysis from smaller tumor samples, including those less than 10,000...
The National Cancer Institute (NCI) awarded a $647,458 Cooperative Agreement under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Massachusetts Institute of Technology (MIT) to develop a novel platform for real-time functional assessment of Acute Myeloid Leukemia (AML) minimal residual disease (MRD) therapeutic vulnerabilities. The project aims to integrate MIT's high-precision biophysical measurements, DeepCell's label-free brightfield imaging and AI-powered sorting,...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $902,046 to Data Driven Bioscience Inc. to perform analytical and clinical validation of the extended applications for their DuoSeq genomic profiling assay. DuoSeq is a novel approach that enables dual DNA and RNA sequencing from a single workflow to provide comprehensive molecular diagnostic readouts for blood cancers, including DNA mutations, copy number alterations,...
The National Cancer Institute (NCI) awarded a $990,771 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Binary Genomics, Inc., a minority-owned for-profit organization located in Madison, CT. The project aims to build clinical data supporting the use of Binary Genomics' circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of lung cancer immunotherapies. The technology leverages epigenetic features to broadly detect ctDNA without...
The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $399,998 Project Grant to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The goal of this 1-year Phase I project is to adapt Darwin Biosciences' existing platform, which was developed under a separate DoD contract, to detect circulating tumor DNA biomarkers for non-small cell lung cancer using saliva and...
This Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,153 to Alelopharma Inc. to develop an ultra-sensitive liquid biopsy test to detect ALK gene fusions in non-small cell lung cancer patients. The goal is to create a diagnostic platform capable of accurately identifying ALK translocation variants in cell-free RNA from blood plasma, which could enable non-invasive cancer screening and monitoring of treatment response....
This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $680,453 to the University of Wisconsin System to develop a liquid biopsy approach using circulating tumor DNA (ctDNA) fragments and machine learning to monitor for the transition between prostate adenocarcinoma and neuroendocrine prostate cancer (NEPC) in metastatic castration-resistant prostate cancer (mCRPC) patients. The key objectives are to: 1) determine if...